Summary
CBDVA is the carboxylic-acid precursor of cannabidivarin (CBDV); heating or vaping will largely decarboxylate it into CBDV. Pre-clinical data suggest anticonvulsant, anti-inflammatory, and 5-HT1A-mediated anti-nausea properties similar to CBDA, but human data are sparse. Like CBD, CBDVA appears to inhibit CYP3A4, CYP2C19 and CYP2C9, so therapeutic drug monitoring is advised when combined with narrow-therapeutic-index medications (e.g., warfarin, clobazam, tacrolimus).
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-90 min | 30-60 min | 2-4 hrs | 2-4 hrs |
| Sublingual | 15-45 min | 20-40 min | 1.5-3 hrs | 1.5-3 hrs |
Tolerance
Build-up
develops over weeks of regular use via CB1 receptor downregulation
Reset
2–4 weeks for most users; heavy users may need longer
Tolerance Decay
Full tolerance
3d
Half tolerance
21d
Baseline
~28d
Effects
Positive
- Anxiolysis
- Reduced inflammation perception
- Anticonvulsant effects
- Mild stimulation at low doses
- Antiemetic effects
- Sedation at higher doses
Positive
- Subtle relaxation
- Mild mood elevation
- Increased focus
Combinations
CBDVA's nerd page
Pharmacology, chemical data, effect profiles, and more
→